About the book
The book aims to focus on the state of the art, pitfalls and perspectives in the diagnostics and treatment of mesothelioma – a peculiar malignant tumour, arising from mesothelial cells that line the pleura, the pericardium and the peritoneum. Mesothelioma is known for strong association with asbestos exposure, difficult surgical treatment and dismal prognosis. However, recent years have yielded significant discoveries, e.g., on germline mutations in BAP1 gene coding BRCA1-associated protein 1, pathogenetic role of inflammation, and innovative treatment approaches like immune checkpoint blockers and PARP inhibitors. The current book intends to summarise the classic concepts and innovations in the diagnostics, treatment and scientific studies of mesothelioma, resulting in a comprehensive reference for clinicians as well as a source of ideas for relevant clinical and basic research. We welcome high-quality original studies, meta-analyses and literature reviews. Case reports are encouraged as an attractive form of scientific article, preferably supplemented by a scientifically sound literature review ensuring a representative insight in the given pathology.
The topics broadly include but are not limited to:
1) Epidemiology and legal aspects of mesothelioma: global and regional incidence and mortality, epidemiological time trends and geographic variations, local experience, limitations and bias affecting diagnostics and coding of mesothelioma, asbestos-related legislation, historical use of asbestos.
2) Causes of mesothelioma: asbestos, asbestiform fibres, non-asbestos causes, germline mutations of BAP1, mismatch repair genes, TP53, BRCA2 and other genes, gene-environment interaction in mesothelioma.
3) Pathogenesis of mesothelioma: asbestos-induced cytotoxicity, role of local inflammation, including M2 macrophages and/or reactive oxygen species among other mechanisms, markers of systemic inflammation (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Glasgow Prognostic Score etc.), BAP1-related molecular pathways, other genetic and epigenetic alterations, miRNAs, stemness, tumour microenvironment and hypoxia.
4) Radiology in diagnostics and staging of mesothelioma: computed tomography, positron emission tomography and magnetic resonance imaging.
5) Tissue-based diagnostics of mesothelioma: cytology, histology and immunohistochemistry, informativity and limitations of the relevant methods, markers for differential diagnosis between benign versus malignant mesothelial cells and primary versus metastatic neoplasms in pleura or peritoneum, diagnostic protocols and algorithms, future developments via digital pathology, machine-based learning etc.
6) Clinical and histological features of BAP1-associated mesothelioma.
7) Liquid biopsy in mesothelioma: proteins, miRNAs, CTC, ctDNA etc.
8) Staging and prognosis of mesothelioma: state of the art, techniques and limitations of current staging systems, survival and prognostic factors, long-term survival.
9) Surgical management of mesothelioma: benefits and controversies of extrapleural pneumonectomy, pleurectomy/decortication (P/D) and extended P/D.
10) Systemic chemotherapy, immune checkpoint inhibitors, BAP1-pathway-targeting agents, PARP inhibitors and other innovations, mechanisms of chemoresistance in mesothelioma.
12) Intracavitary chemo- and/or photodynamic therapy.
13) Peritoneal mesothelioma (PM): cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy.
14) Rare locations and histological types: pericardiac mesothelioma, multicystic mesothelioma etc.
15) Mesothelioma in wild and domestic animals.
16) Communication and support: communicating diagnosis to the patient, palliative treatment, nutritional maintenance and psychological support.